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Virus-like particles (VLPs) constitute a promising approach for recombinant vaccine development. They are
robust, safe, versatile and high immunogenic supra-molecular structures that closely mimic the native
conformation of the viruses without carrying its genetic material. HIV-1 Gag VLPs share similar characteristics
with wild type Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, making them a suitable
platform to express the Spike membrane protein to generate a potential vaccine candidate for COVID-19. This
work proposes a methodology for the generation of SARS-CoV-2 VLPs by its co-expression with HIV-1 Gag
protein by transient transfection of HEK 293 cultures. We first evaluated the cellular co-expression of SARSCoV-2 Spike glycoprotein with HIV-1 Gag: confocal microscopy analysis showed that after its expression, native
envelope Spike glycoprotein travels to the plasmatic membrane of the HEK 293 producer cells, where it colocalizes with Gag::eGFP (Figure 1.A,B) and Spike-functionalized VLPs (S-VLP) generation occurs. Electron
microscopy observations of the S-VLPs led us to conclude that they had no significant structural differences with
Gag-based non functionalized VLPs (G-VLPs). Spike protein presence was confirmed by western blot (Figure
1.C) and by immunogold labeling at the surface of S-VLPs (Figure 1.D), a key feature to present immunogenic
SARS-CoV-2 epitopes to patient’s immune system when used as vaccine. Further, we optimized the production
bioprocess using design of experiments to increase S-VLP productivity. Using this approach, we identified the
transfection conditions maximizing the cellular population co-expressing simultaneously Gag and S proteins.
The model predicted a double positive population of 57.5±2.3% for the optimal transfection condition, which was
validated and then implemented to transfect a 1L stirred tank bioreactor. The bioreactor production was carried
out satisfactorily achieving similar behavior to the parallel Erlenmeyer shake flasks in terms of cellular growth,
Spike concentration, VLP concentration and purity of the produced S-VLPs. The production was then followed
by a downstream purification process consisting in two clarifications, an ion exchange and a size exclusion
chromatography. Overall, the DSP process had a low yield in terms of VLP recovery but highly succeeded in
concentrating and purifying the desired S-VLPs while generating a final product with low undesired
contaminants. The approach proposed could be expanded to produce additional Gag-based VLPs against
different diseases or COVID-19 variants.

Figure 1 – Spike protein cellular localization and characterization of the produced S-VLPs. (A,B): Colocalization of Spike (red) and Gag (green) can be observed at (A): cells external boundary and (B): Crosssection of the plasmatic membrane. Cell nuclei is shown as blue. (C): Western Blot of purified S-VLPs and GVLPs. Top: anti SARS-CoV-2 S2 Spike. Bottom: anti HIV-1 p24. Both S-VLPs and G-VLPs showed HIV-1 Gag
bands, while only S-VLPs showed Spike bands. (D): Electron microscopy images of the Gold-immunolabeled
S-VLPs showing S protein localization (arrows) on the surface of the chimeric VLPs.
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